Gaps or links between hormonal therapy and schizophrenia? (Review)

Trifu,Simona   Corina; Istrate,Diana; Miruna,Drăgoi  Ana

doi:10.3892/etm.2020.9017

Gaps or links between hormonal therapy and schizophrenia? (Review)

Authors:
- Simona Corina Trifu
- Diana Istrate
- Drăgoi Ana Miruna
View Affiliations

Affiliations: Department of Clinical Neurosciences, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of General Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Psychiatry, ‘Prof. Dr. Alexandru Obregia’ Clinical Psychiatry Hospital, 041914 Bucharest, Romania
Published online on: July 16, 2020 https://doi.org/10.3892/etm.2020.9017
Pages: 3508-3512
Copyright: © Trifu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Schizophrenia is considered the most severe and debilitating psychiatric disorder. During the 80's, first reports on abnormalities of the schizophrenic brain which could be objectively observed on MRI, CT scans and other imagistic techniques were published. This showed that schizophrenia is a disorder that goes beyond the functional aspect of the symptomatology. The ties between psychiatry and endocrinology are easily observed, even empirically, by any mental health practitioner, and mirrored by endocrinology specialists. Disorders related to menstruation phase of the menstrual cycle have a code in DSM‑V, people expect women ‘to have mental disturbances’ during puberty, pregnancy, menopause and other periods of life known to cause a hormonal storm. Leaving aside those simple and common beliefs, any mental health specialist can observe the differences between men and women when it comes to psychopathology, and the differences between male and female patients when it comes to a severe disorder such as schizophrenia. Males present more severe symptoms; their evolution is worse and they tend to have more medico‑legal issues. On the contrary, the current available treatments for schizophrenia tend to have some side effects easily observed by endocrinologists: from gynecomastia to breast asymmetry in women, hyperprolactinemia, weight gain and other metabolic disorders, the clinic shows us regularly what the science has already told us; that the impact of hormones on the developing brain, starting in utero and going on through life may hold the key to finding better treatments for debilitating disorders such as schizophrenia. This mini‑review is focused on the role of estrogen in the evolution of schizophrenia and on reporting trials that showed how hormonal therapy (used mainly for breast cancer and osteoporosis) can improve the outcome of patients with schizophrenia.

View Figures

View References

1	Seeman P: All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther. 17:118–132. 2011.PubMed/NCBI View Article : Google Scholar
2	Trifu S, Vladuti A and Popescu A: Neuroendocrine aspects of pregnancy and postpartum depression. Acta Endocrinol (Bucur). 15:410–415. 2019.PubMed/NCBI View Article : Google Scholar
3	Di Paolo T: Modulation of brain dopamine transmission by sex steroids. Rev Neurosci. 5:27–41. 1994.PubMed/NCBI View Article : Google Scholar
4	Trifu S and Gutt A: Interpretative process - from utilization of predominant to psychotic decompensation. Procedia Soc Behav Sci. 187:429–433. 2014.
5	Picchioni MM and Murray RM: Schizophrenia. BMJ. 335:91–95. 2007.PubMed/NCBI View Article : Google Scholar
6	Kiliçaslan EE, Erol A, Zengin B, Çetinay Aydin P and Mete L: Association between age at onset of schizophrenia and age at menarche. Noro Psikiyatr Ars. 51:211–215. 2014.PubMed/NCBI View Article : Google Scholar
7	Lindamer LA, Lohr JB, Harris MJ and Jeste DV: Sex, estrogen, and schizophrenia. Psychopharmacol Bull. 33:221–228. 1997.PubMed/NCBI
8	Castle DJ, Abel K, Takei N and Murray RM: Sex differences in schizophrenia: Hormonal effect or subtypes? Schizophr Bull. 21:1–12. 1995.PubMed/NCBI View Article : Google Scholar
9	Riecher-Rössler A and Häfner H: Schizophrenia and oestrogens - is there an association? Eur Arch Psychiatry Clin Neurosci. 242:323–328. 1993.PubMed/NCBI View Article : Google Scholar
10	Trifu S, Mihailescu R, Stegarescu S and Ion I: Evolutional perspective over some key-aspects in psychiatry In: Theoretical and Applied in Psychology (SICAP23): Psychology and ongoing development. Editografica, Bologna, p179, 2016.
11	Guz H: Schizophrenia and sex. Anatol J Psychiatry. 3:180–185. 2000.
12	Trifu S: Dissociative identity disorder Psychotic functioning and impairment of growing-up processes. J Educ Sci Psychol. 9:102–108. 2019.
13	McEwen BS and Alves SE: Estrogen actions in the central nervous system. Endocr Rev. 20:279–307. 1999.PubMed/NCBI View Article : Google Scholar
14	Huber TJ, Borsutzky M, Schneider U and Emrich HM: Psychotic disorders and gonadal function: Evidence supporting the oestrogen hypothesis. Acta Psychiatr Scand. 109:269–274. 2004.PubMed/NCBI View Article : Google Scholar
15	Bergemann N, Mundt C, Parzer P, Pakrasi M, Eckstein-Mannsperger U, Haisch S, Salbach B, Klinga K, Runnebaum B and Resch F: Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: Results of a placebo-controlled double-blind study. Schizophr Res. 74:125–134. 2005.PubMed/NCBI View Article : Google Scholar
16	Nopoulos P, Flaum M and Andreasen NC: Sex differences in brain morphology in schizophrenia. Am J Psychiatry. 154:1648–1654. 1997.PubMed/NCBI View Article : Google Scholar
17	Bryant NL, Buchanan RW, Vladar K, Breier A and Rothman M: Sex differences in temporal lobe structures of patients with schizophrenia: A volumetric MRI study. Am J Psychiatry. 156:603–609. 1999.PubMed/NCBI View Article : Google Scholar
18	Rao ML and Kölsch H: Effects of estrogen on brain development and neuroprotection - implications for negative symptoms in schizophrenia. Psychoneuroendocrinology. 28 (Suppl 2):83–96. 2003.PubMed/NCBI View Article : Google Scholar
19	Reilly TJ, Sagnay de la Bastida VC, Joyce DW, Cullen AE and McGuire P: Exacerbation of psychosis during the perimenstrual phase of the menstrual cycle: Systematic review and meta-analysis. Schizophr Bull. 46:78–90. 2020.PubMed/NCBI View Article : Google Scholar
20	Michael Deans PJ, Shum C, Perfect L, Conforti M, Duarte R, Bhattacharyya S, Brandon N, Price J and Srivastava D: Investigating the mechanisms underlying the beneficial effects of estrogens in schizophrenia. Schizophr Bull. 44 (Suppl 1)(S105)2018.
21	Bergemann N, Parzer P, Runnebaum B, Resch F and Mundt C: Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med. 37:1427–1436. 2007.PubMed/NCBI View Article : Google Scholar
22	Ray P, Mandal N and Sinha VK: Change of symptoms of schizophrenia across phases of menstrual cycle. Arch Women Ment Health. 23:113–122. 2020.PubMed/NCBI View Article : Google Scholar
23	Choi SH, Kang SB and Joe SH: Changes in premenstrual symptoms in women with schizophrenia: A prospective study. Psychosom Med. 63:822–829. 2001.PubMed/NCBI View Article : Google Scholar
24	Hodgetts S and Hausmann M: Antipsychotic effects of sex hormones and atypical hemispheric asymmetries. Cortex. 127:313–332. 2020.PubMed/NCBI View Article : Google Scholar
25	Lascurain MB, Camuñas-Palacín A, Thomas N, Breadon C, Gavrilidis E, Hudaib AR, Gurvich C and Kulkarni J: Improvement in depression with oestrogen treatment in women with schizophrenia. Arch Womens Ment Health. 23:149–154. 2019.PubMed/NCBI View Article : Google Scholar
26	Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt CH and Resch F: Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Women Ment Health. 5:119–126. 2002.PubMed/NCBI View Article : Google Scholar
27	Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B and Josiassen RC: Prevalence of hyperprolactinemia in schizophrenia: Association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 65:1491–1498. 2004.PubMed/NCBI View Article : Google Scholar
28	Ishioka M, Yasui-Furukori N, Sugawara N, Furukori H, Kudo S and Nakamura K: Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatr Dis Treat. 11:477–484. 2015.PubMed/NCBI View Article : Google Scholar
29	Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M and Dean B: A role for estrogen in schizophrenia: Clinical and preclinical findings. Int J Endocrinol. 2015(615356)2015.PubMed/NCBI View Article : Google Scholar
30	Begemann MJ, Dekker CF, van Lunenburg M and Sommer IE: Estrogen augmentation in schizophrenia: A quantitative review of current evidence. Schizophr Res. 141:179–184. 2012.PubMed/NCBI View Article : Google Scholar
31	Heringa SM, Begemann MJ, Goverde AJ and Sommer IE: Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Schizophr Res. 168:603–613. 2015.PubMed/NCBI View Article : Google Scholar
32	Wang Q, Dong X, Wang Y and Li X: Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A meta-analysis of randomized controlled trials. Arch Women Ment Health. 21:31–41. 2018.PubMed/NCBI View Article : Google Scholar
33	Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L and Akhondzadeh S: Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: A randomized double-blind and placebo controlled trial. Daru. 22(55)2014.PubMed/NCBI View Article : Google Scholar
34	Usall J, Huerta-Ramos E, Labad J, Cobo J, Núñez C, Creus M, Parés GG, Cuadras D, Franco J, Miquel E, et al: RALOPSYCAT Group: Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial. Schizophr Bull. 42:309–317. 2016.PubMed/NCBI View Article : Google Scholar
35	Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M and Akhondzadeh S: A placebo-controlled study of raloxifene added to risperidone in men with chronic schizophrenia. Acta Med Iran. 53:337–345. 2015.PubMed/NCBI
36	Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial Multiple outcomes of raloxifene evaluation. JAMA. 281:2189–2197. 1999.PubMed/NCBI View Article : Google Scholar
37	Ladea M and Prelipceanu D: Markers of vulnerability in schizophrenia. J Med Life. 2:155–164. 2009.PubMed/NCBI
38	Ladea M, Barbu CM and Juckel G: Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data. Psychiatr Danub. 27:364–370. 2015.PubMed/NCBI
39	Shivakumar V and Venkatasubramanian G: Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia. Indian J Psychiatry. 54(394)2012.PubMed/NCBI View Article : Google Scholar
40	Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M and Davis SR: Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: A randomized clinical trial. JAMA Psychiatry. 73:947–954. 2016.PubMed/NCBI View Article : Google Scholar
41	de Boer J, Prikken M, Lei WU, Begemann M and Sommer I: The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A systematic review and meta-analysis. NPJ Schizophr. 4(1)2018.PubMed/NCBI View Article : Google Scholar
42	Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, Micluția I, Tiugan A, Păcală B, Grecu IG, et al: Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely Ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: A randomized controlled trial. J Clin Psychiatry. 78:e758–e765. 2017.PubMed/NCBI View Article : Google Scholar
43	Trifu S and Trifu AD: Receptor profiles of atypical antipsychotic molecules. UPB Sci Bull. 82:113–128. 2020.
44	Ellis AJ, Hendrick VM, Williams R and Komm BS: Selective estrogen receptor modulators in clinical practice: A safety overview. Expert Opin Drug Saf. 14:921–934. 2015.PubMed/NCBI View Article : Google Scholar
45	Vogel VG, Costantino JP, Wickerham DL, Cronin WM and Wolmark N: The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer. 3:153–159. 2002.PubMed/NCBI View Article : Google Scholar
46	Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 65:125–134. 2001.PubMed/NCBI View Article : Google Scholar
47	Raveendranathan D, Shivakumar V, Jayaram N, Rao NP and Venkatasubramanian G: Beneficial effects of add-on raloxifene in schizophrenia. Arch Women Ment Health. 15:147–148. 2012.PubMed/NCBI View Article : Google Scholar
48	Khan MM: Translational significance of selective estrogen receptor modulators in psychiatric disorders. Int J Endocrinol. 2018(9516592)2018.PubMed/NCBI View Article : Google Scholar
49	Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S, Gurvich C, Fitzgerald PB and Burger H: Estrogens and men with schizophrenia: Is there a case for adjunctive therapy? Schizophr Res. 125:278–283. 2011.PubMed/NCBI View Article : Google Scholar
50	Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, O'Donnell M, Galletly C, Liu D, Balzan R, et al: Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 20:685–694. 2015.PubMed/NCBI View Article : Google Scholar
51	Kindler J, Weickert CS, Skilleter AJ, Catts SV, Lenroot R and Weickert TW: Selective estrogen receptor modulation increases hippocampal activity during probabilistic association learning in schizophrenia. Neuropsychopharmacology. 40:2388–2397. 2015.PubMed/NCBI View Article : Google Scholar
52	Faraone SV, Chen WJ, Goldstein JM and Tsuang MT: Sex differences in age at onset of schizophrenia. Br J Psychiatry. 164:625–629. 1994.PubMed/NCBI View Article : Google Scholar
53	Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD and Conus P: Sex differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res. 114:17–24. 2009.PubMed/NCBI View Article : Google Scholar
54	Döpfner M, Plück J, Berner W, Fegert JM, Huss M, Lenz K, Schmeck K, Lehmkuhl U, Poustka F and Lehmkuhl G: Mental disturbances in children and adolescents in Germany. Results of a representative study: Age, sex and rater effects. Z Kinder Jugendpsychiatr Psychother. 25:218–233. 1997.PubMed/NCBI(In German).
55	Kulkarni J, Gavrilidis E, Worsley R, Van Rheenen T and Hayes E: The role of estrogen in the treatment of men with schizophrenia. Int J Endocrinol Metab. 11:129–136. 2013.PubMed/NCBI View Article : Google Scholar